BELFAST, Northern Ireland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- CV6 Therapeutics (NI) Ltd. ("CV6"), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and ...
BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics ('CV6'), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and ...
CV6 Therapeutics (NI) Ltd. has secured US$9.2 million to progress its lead oncology asset CV6-168 into a first-in-human phase Ia trial and perform further scientific development work. CV6-168 is a ...
CV6 Therapeutics will conduct further research with Queen’s University Belfast while clinical trials are going on. Belfast-based CV6 Therapeutics has raised £8m to invest in clinical trials and ...
CV6 Therapeutics is developing next-generation cancer treatment, and it is looking backwards to make the future better. Emily McDaid reports. CV6 Therapeutics doesn’t replace traditional chemotherapy; ...
When Belfast-based CV6 Therapeutics (NI) Limited (CV6) announced it secured $9.2 million in funding to advance its primary oncology asset into a first-in-human Phase 1a clinical trial last November, ...
The MarketWatch News Department was not involved in the creation of this content. CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results